Enterprise Value

35.58M

Cash

54.92M

Avg Qtr Burn

-11.64M

Short % of Float

3.99%

Insider Ownership

14.13%

Institutional Own.

34.07%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DKN-01 (+/- Paclitaxel) Details
Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer

Phase 3

Update

DKN-01 (Bevacizumab & Chemotherapy) Details
Esophageal cancer, Cancer, Colorectal cancer

Phase 2

Data readout

DKN-01 + pembrolizumab Details
Endometrial cancer, Cancer

Phase 2

Data readout

DKN-01 (+ tislelizumab +/- CAPOX) Details
Gastroesophageal junction tumors, Cancer, Gastric cancer

Phase 2a

Data readout

FL-301 Details
Cancer, Pancreatic cancer, Gastric cancer

Phase 1

Data readout

Failed

Discontinued